Immunosuppressive and immunomodulatory treatment for myocarditis

Current Opinion in Cardiology

Volumn 11, Issue 3, 1996, Pages 310-324

  Maisch, Bernhard ^a   Herzum, Matthias ^a   Hufnagel, Günter ^a   Schonian, Ute ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON A-D; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; LEVAMISOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TACROLIMUS; TUMOR NECROSIS FACTOR;

HEART HEMODYNAMICS; HEART MUSCLE BIOPSY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VIRUS GENOME; VIRUS MYOCARDITIS; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MYOCARDITIS; PERICARDITIS; RANDOMIZED CONTROLLED TRIALS; REMISSION, SPONTANEOUS;

EID: 0029888747     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199605000-00012     Document Type: Review

References (126)

1. Richardson D, McKenna W, Bristow M, Maisch B, Mautner B, O'Connel J, Olsen E, Thiere G, Goodwin J, Gyarfas J, et al.: WHO/ISFC Task Force definition and classification of cardiomyopathies. Circulation 1996, 93:23-24.
2. Levine HD: Virus myocarditis: a critique of the literature from clinical, electrocardiographic and pathological stand-points. Am J Med Sci 1979, 277:132-143.
3. Giesecke J: The long-term prognosis in acute myocarditis. Eur Heart J 1987, 8(suppl J):251-253.
4. Aretz HT, Billingham ME, Edwards WD, et al.: Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol 1986, 1:3-14.
5. Doerr W: Morphologie der Myokarditis [In German]. Verh Dtsch Ges Inn Med 1956, 77:301-335.
6. Shanes JG, Gahli J, Billingham ME, et al.: Interobserver variability in the pathological interpretation of endomyocardial biopsy results. Circulation 1987, 75:401-405.
7. Hahn EA, Hartz VL, Moon TE, O'Connell JB, Herskowitz A, McManus BM, Mason JW, for the Myocarditis Treatment Trial Investigators: The Myocarditis Treatment Trial: design, methods and patient enrollment Eur Heart J 1995,16(suppl O):162-167. This description of the study design of the American Myocarditis Treatment Trial details its methods for diagnosis and the rationale for the immunosuppressive treatment. It outlines that only 9.6% of the patients screened under the suspicion of myocarditis by the investigators met the Dallas criteria for myocarditis.
8. Mason JW, O'Connell JB, Herskowitz A, et al.: A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995, 333:269-275. Results from the long-awaited Myocarditis Treatment Trial indicate neither hemodynamic nor prognostic benefit in patients undergoing immunosuppression with cyclosporine and corticosteroids after a 6-month treatment. Due to methodologic shortcomings at the time of its initiation, the trial could not classify patients according their immunologic (autoreactive) or viral status (PCR/in situ hybridization-positive for enteroviruses, cytomegalovirus, Epstein-Barr Virus, adenovirus, borreliosis, and others).
9. McKenna WJ, Davies MJ: Immunosuppression for myocarditis [editorial]. N Engl J Med 1995, 333:312-313. Editorial in which the need for better diagnostic criteria to classify patients with dilated cardiomyopathy both histologically and etiologically is emphasized.
10. Cunnion RE, Parillo JE: Immunosuppressive therapy for myocarditis [letter]. N Engl J Med 1995, 333:1713. Emphasizes the need for further research to identify subgroups of patients with dilated cardiomyopathy who may benefit from immunosuppressive treatment.
11. Maisch B, Camerini F, Schultheiss H-P: Immunosuppressive therapy for myocarditis [letter]. N Engl J Med 1995, 333:1713. Pinpoints the major shortcomings of the Myocarditis Treatment Trial: inadequate or too stringent criteria for myocarditis due to the lack of immunohistochemistry and limitation to cellular infiltrates as signs of inflammation despite the fact that immunoglobulins, cytokines, and adhesion molecules respresent similarity relevant markers of inflammation. In addition, the duration of the trial appeared too short in the view of the fact that at the time of discontinuation there were nine deaths in the control group but only four deaths in the treatment arm. Also, the selection of cyclosporine as the right drug for this disease is questioned.
12. Cooper LT, Shabetai R: Immunosuppressive therapy for myocarditis. N Engl J Med 1995, 333:1713-1714. Points out that in the rare case of giant cell myocarditis, immunosuppression is contraindicated. The authors have started a giant cell myocarditis study group to investigate this particular subgroup of myocarditis patients more intensively.
13. Mason JW, O'Connell JB, McManus BM: Immunosuppressive therapy for myocarditis [authors' reply]. N Engl J Med 1995, 333:1714. The authors reply to the other letters to the editor.
14. Maisch B, Herzum M, Hufnagel, G, Bethge C, Schänian U: Immunosuppressive treatment for myocarditis and dilated cardiomyopathy. Eur Heart J 1995, 16(suppl O): 153-161. Critical overview on immunosuppressive treatment of myocarditis in humans and experimental animals. The authors also develop their rationale for immunosuppressive treatment in virus-negative patients with chronic myocarditis. The treatment concept also includes antiviral and immunomodulating drugs, which have been introduced in the double-blind randomized ESETCID trial.
15. Kühl U, Schultheiss H-P: Treatment of chronic myocarditis with corticosteroids. Eur Heart J 1995, 16(suppl O) 168-172. Report on the uncontrolled treatment of patients with chronic myocarditis based on immunohistochemical analysis. After a 4- to 8-week period of conventional treatment, corticosteroids were given to patients who had not improved spontaneously. Improvement of ejection fraction was noted in 64% of patients.
16. Maisch B, Hufnagel G, Schönian U, Hengstenberg C for the ESETCID Investigators: The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Eur Heart J 1995, 16 (Suppl O):173-175. Study design and rationale for the ESETCID trial, which uses three treatment arms in active (Dallas criteria) and chronic (< 2.5 cells/high-power field) myocarditis: azathioprine and prednisone in autoreactive, virus-negative myocarditis, cytomegalovirus hyperimmunoglobulins in cytomegalovirus-positive myocarditis, and interferon alfa in enterovirus-positive patients with myocarditis. The hemodynmic entrance criterion is an ejection fraction of less than 45% in gated blood pool scintigraphy.
17. Maisch B: Immunologic regulator and effector function in perimyocarditis, postmyocarditic heart muscle disease and dilated cardiomyopathy. Basic Res Cardiol 1986, 81(suppl 1):217-242.
18. Maisch B, Bauer E, Hufnagel G, Pfeifer U, Rohkamm R: The use of endomyocardial biopsy in heart failure. Eur Heart J 1988, 9(suppl H):59-71.
19. Kühl U, Daun B, Seeberg B, Schultheiss H-P, Strauer BE: Dilated cardiomyopathy: a chronic myocarditis? lmmunohistological characterization of lymphocytic infiltrates. Herz 1992, 17:97-106.
20. Hershkowitz A, Baughman KL, Rose NR et al.: Introduction of major histocompatibility (MHC) antigens on myocardial cells in patients with active myocarditis and idiopathic cardiomyopathy. In New Concepts in Viral Heart Disease. Edited by Schultheiss HP, Berlin, Heidelberg, New York: Springer-Verlag; 1988:93-104.
21. Hufnagel G, Maisch B: Expression of MHC class I and II antigens and the IL-2 receptor In rejection, myocarditis and dilated cardiomyopathy. Eur Heart J 1991, 12(suppl D):137-140.
22. Hengstenberg C, Rose ML, Olsen EGJ, Maisch B: Immune response to the endothelium In myocarditis, dilated cardlomyopathy and rejection after heart transplantation. Eur Heart J 1991, 12(suppl D):144-146.
23. Maisch B, Weyerer O, Hufnagel G, Hengstenberg C, Schönian U, Haverich A, Kochsiek K: The vascular endothelium as target of humoral autoreactivity In myocarditis and rejection. Z Kardiol 1989, 78(suppl 6):95-99.
24. Parillo JE, Cunnion RE, Epstein SE, Parker MM, Suffredini AF, Brenno M, Schaer GL, Palmeri ST, Cannon RO, Ailing D, Wittes JT, Ferrans VJ, Rodriguez ER, Fauci AS: A prospective randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989, 321:1061-1068.
25. Maisch B: Myocarditis. Curt Opin Cardiol 1990, 5:320-327.
26. Bowles NE, Richardson PJ, Olsen EGJ, Archard LC: Detection of coxsackie-B-virus-speclfic RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1986, 1:1120-1123.
27. Kandolf R, Hofschneider PH: Effect of interferon on the replication of coxsackie B3 virus in cultured human foetal heart cells. In Viral Heart Disease. Edited by Bolte HD. New York: Springer-Verlag; 1984:57-63.
28. Kandolf R, Ameis D, Kirchner P, Canu A, Hofschneider PH: In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. Proc Natl Acad Sci U S A 1987, 84:6272-6276.
29. Tracy S: A comparison of genomic homologies among the coxsacklevirus B group: use of fragments of the cloned coxsackievirus B3 genome as probes. J Gen Virol 1984, 65:2167-2172.
30. Tracy S, Hufnagel G, Chapman N: Interesting problems in enteroviral inflammatory heart disease. Herz 1992, 17:79-84.
31. Maisch B, Wendl J: Cytomegalovirus DNA in endomycardial biopsies of patients with (peri)myocarditis [abstract]. Eur Heart J 1989, 9(suppl):1000.
32. Schönian U, Crombach M, Maisch B: Does CMV infection play a role in myocarditis? New aspects from in-situ hybridization. Eur Heart J 1991, 12(suppl D):65-99.
33. Schönian U, Crombach M, Maisch B: Assessment of cytomegalovirus DNA and protein expression in patients with myocarditis. Clin Immunol Immunopathol 1993, 68:229-233.
34. Martin AB, Webber S, Fricker FJ, Jaffe R, Demmler G, Keamey D, Zhang Y-H, Bodurtha J, Gelb B, Ni J, Bricker T, Towbin JA: Acute myocarditis: rapid diagnosis by PCR in children. Circulation 1994, 90:330-339.
35. Herzum M, Huber SA, Weller R, Grebe R, Maisch B: Treatment of experimental murine coxsackie B3 myocarditis. Eur Heart J 1991, 12(suppl D):200-201.
36. Herzum M, Maisch B: Humoral and cellular immune response in human myocarditis and dilated cardiomyopathy. Pathol Immunopathol Res 1988, 7:240-250.
37. Herzum M, Ruppert V, Küytz B, Jomaa H, Nakamura I, Maisch B: Coxsackievirus B 3 infection leads to cell death of cardiac myocytes. J Mol Cell Cardiol 1994, 26:907-913. Important new data demonstrating that cardiac myocytes can be damaged in vitro by cardiovirulent coxsackie virus B3 alone.
38. Maisch B, Trostel-Soeder R, Stechemesser E, Berg PA, Kochsiek K: Diagnostic relevance of humoral and cell-mediated immune reactions in patients with acute viral myocarditis. Clin Exp Immunol 1982, 48:533-545.
39. Maisch B, Bauer E, Cirsi M, Pankuweit S, Schönian U, Kochsiek K: Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral protein in coxsackie virus B3 and B4 myocarditis-characterization and pathogenetic relevance. Circulation 1993, 87(suppl 4):49-65.
40. Schultheiss H-P: The significance of autoantibodies against the ADP/ATP carrier for the pathogenesis of myocarditis and dilated cardiomyopathy clinical and experimental data. Springer Semin Immunopathol 1989, 11:15-30.
41. Kühl U, Melzner B, Schäfer B, Schultheiss HP, Strauer BE: The Cachannel as cardiac autoantigen. Eur Heart J 1991, 12(suppl D):99-104.
42. Limas CJ, Limas C: Beta-adrenoceptor antibodies and genetics in dilated cardiomyopathy: an overview and review. Eur Heart J 1991, 12(suppl D):175-177.
43. Wallukat G, Morwinski M, Kowal K, Förster A, Boewer V, Wollenberg A: Autoantibodies against the β-adrenergic receptor in human myocarditis and dilated cardiomyopathy: β-adrenergic agonism without desensitlzation. Eur Heart J 1992, 17(suppl D):178-181.
44. Maisch B, Lotze U, Schneider J, Kochsiek K: Antibodies to human sinus node in sick sinus syndrome. PACE Pacing Clin Electrophysiol 1986, 9:1101-1112.
45. Lotze U, Maisch B: Humoral immune response to cardiac conducting tissue. Springer Semin Immunopathol 1989, 11:409-422.
46. Samsonov M, Nassonov E, Kostin S, Samk A, Alexandrova L, Masenko V, Naumov V, Mareev V, Shevlyagin S, Zhadanov V: Serum neopterin: possible immunological marker of myocardial inflammation in patients with dilated heart muscle disease. Eur Heart J 1991, 12(suppl D):151-153.
47. Maisch B, Salzer E, Ertl G, Kochsiek K: Pericardial thickness and pericardial effusion as echocardiographic markers of acute or past pericardial, perimyocardial and myocardial disease. Eur Heart J 1987, 8(suppl J):109-114.
48. Maisch B, Drude L: Pericardioscopy: a new diagnostic tool In inflammatory disease of the pericardium. Eur Heart J 1991, 12(suppl D):2-6.
49. Maisch B, Drude L: Epi- and pericardial biopsy by pericardioscopy. Circulation 1992, 82(suppl 3):417[A1658].
50. Lyden DC, Feran M, Olszewski J, Job LP, Huber SA: Coxsackievirus B-3 induced myocarditis: effect of sex steroids on viremia and infectivity of cardiocytes. Am J Pathol 1987, 126:432-438.
51. Weller A, Huber S, Herzum M: Genetics in viral heart disease. J Mol Genet 1982, 27:332-338.
52. Kandolf R, Hofschneider PH: Molecular cloning of the genome of a cardiotropic coxsackie B3 virus: full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells. Proc Natl Acad Sci U S A 1985, 82:4818-4822.
53. Mall G, Klingel K, Albrecht M, Seemann M, Rieger P, Kandolf R: Natural history of coxsackievirus B3-induced myocarditis in ACCA/Sn mice: viral persistence demonstrated by quantitative in situ hybridization histochemistry. Eur Heart J 1991, 12(suppl D):121-123.
54. Matsumori A, Kawai C: Immunomodulating therapy in experimental myocarditis. Springer Semin Immunopathol 1989, 11:77-88.
55. Matsumori A, Yamada T, Kawai C: Immunomodulating therapy in viral myocarditis: effects of tumour necrosis factor, interleukin 2 and anti-interteukin-2 receptor antibody in an animal model. Eur Heart J 1991, 12(suppl D):203-205.
56. Matsumori A: Lessons from animal experiments in myocarditis. Herz 1992, 17:107-111.
57. Woodruff JF, Woodruff JJ: Involvement of T lymphocytes in the pathogenesis of coxsacklevirus B3 heart disease. J Immunol 1974, 113:1726-1734.
58. Huber SA, Job LP: Cellular immune mechanisms in coxsackievirus group B, type 3 induced myocarditis in Balb/c mice. In Myocardial injury. Edited by Spitzer JJ. New York: Plenum Publishing; 1983:491-508.
59. Huber SA, Lodge PA: Coxsackie B-3 myocarditis in Balb/c mice: evidence for autoimmunity to myocyte antigens. Am J Pathol 1984, 116:21-29.
60. Guthrie M, Lodge PA, Huber SA: Cardiac injury in myocarditis induced by coxsackievirus group B, type 3 in Balb/c mice is mediated by Lyt2+ cytolytic lymphocytes. Cell Immunol 1984, 88:558-567.
61. Seko Y, Yagita H, Okumura K, Yazaki Y: T-cell receptor Vb gene expression in infiltrating cells in murine hearts with acute myocarditis caused by coxsackievirus B3. Circulation 1994, 89:2170-2175. Sophisticated study demonstrating T-cell receptor and gene expression in the T cells that are found in murine myocarditis.
62. Seko Y, Matsuda H, Kalo K, Hashimoto Y, Yagita H, Okumura K, Yazaki Y: Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3. J Clin Invest 1993, 91:1327-1336.
63. Seko Y, Shinkai Y, Kawasaki A, Yagita H, Okumura K, Yazaki Y: Evidence of perforin-mediated cardiac myocyte injury in acute murine myocarditis caused by coxsackievirus B3. J Pathol 1993, 170:53-58.
64. Yamada T, Matsumori A, Sasayama S: Therapeutic effect of anti-tumor necrosis factor-a antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 1994, 89:846-851. Tumor necrosis factor which is found in various diseases, eg, myocarditis and end-stage heart failure, may contribute to heart failure and myocytolysis. The damage can be partly prevented by the respective antibodies.
65. Huber SA, Polgar J, Schultheiss P, Schwimmbeck P: Augmentation of pathogenesis of coxsackievirus B3 infections in mice by exogenous administration of interleukin-1 and interleukin-2. J Virol 1994, 68:195-206. Cytokines such as interleukin-1 and interleukin-2 exacerbate viral damage. Myocytolysis is therefore the final result of viral, lymphocyte-induced, and cytokine-mediated damage.
66. Kishimoto C, Kuroki Y, Hiraoka Y, Ochiai H, Kurokawa M, Sasayama S: Cytokine and murine coxsackievirus B3 myocarditis: interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage. Circulation 1994, 89:2836-2842. Remarkable experimental study showing the stage-dependent effect of interleukin-2. In the acute inflammatory stage it is beneficial (because antiviral), but in the later stages it may exacerbate (autoreactive) myocarditis.
67. Lyden DC, Huber SA: Aggravation of coxsackie virus B-3 induced myocarditis and increase in cellular immunity of myocyte antigens in pregnant Balb/c mice and animals treated with progesterone. Cell Immunol 1984, 87:462-472.
68. Lyden D, Olszewski J, Huber SA: Influence of sex hormones on coxsackie virus group B, type 3 induced myocarditis in Balb/c mice. Eur Heart J 1987, 8(suppl J):389-391.
69. Huber SA, Pfaeffle B: Differential Th1 and Th2 cell response in male and female BALB/c mice infected with coxsackievirus group B type 3. J Virol 1994, 68:5126-5132. Male BALB/c mice are prone to coxsackievirus B3 myocarditis due to a different T cell repertoire.
70. Billingham M: In Viral Infections of the Heart. Edited by Banatvala JE. Arnold Publications; 1993:47.
71. Strom TB: Immunosuppressive agents in renal transplantation. Kidney Int 1984, 26:353-362.
72. Kilbourne ED, Wilson CB, Perrier D: The induction of gross myocardial lesions by a coxsackie (pleurodynia) virus and cortisone. J Clin Invest 1956, 35:362-367.
73. Tomioka N, Kishimoto C, Matsumori A, Kawai C: Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol 1986, 7:868-872.
74. Mason JW, Billingham ME, Ricci DR: Treatment of acute inflammatory myocarditis assisted by endomyocardial biopsy. Am J Cardiol 1980, 45:1037-1044.
75. Maisch B, Schönian U, Hengstenberg C, Herzum M, Hufnagel G, Bethge C, Bittinger A, Neumann K: Immunosuppressive treatment in autoreactive myocarditis: results from a controlled trial. Postgrad Med J 1994, 70(suppl 1):29-34. One of the few controlled clinical trials showing modest benefit for immunosuppression (azathioprine and prednisone) given for 3 months in chronic virus-negative myocarditis. New York Heart Association class and hemodynamics were improved. The infiltrate was eliminated. However, spontaneous improvement in the control group, although fairly low, was noted as well.
76. Schultheiß HP, Kühl U, Janda I, Schanwell M, Strauer BE: Immunosuppressive therapy in myocarditis. Herz 1992, 17:112-121.
77. Eckstein R, Mempel W, Bolte HD: Reduced suppressor cell activity in congestive cardiomyopathy and in myocarditis. Circulation 1982, 65:1224-1229.
78. O'Connell JB, Reap Ea, Robinson JA: The effect of cyclosporine on acute murine coxsackie B3 myocarditis. Circulation 1986, 73:353-355.
79. Rager-Zisman B, Allison AC: Effects of immunosuppression on coxsackie B3 virus infection in mice, and passive protection by circulating antibody. J Gen Virol 1973, 19:339-342.
80. Khatib R, Khatib G, Chason JL, Lerner AM: Alterations in coxsackievirus B4 heart muscle disease in ICR Swiss mice. J Gen Virol 1983, 64:231-243.
81. Hanawa H, Kodama M, Zhang S, Izumi T, Shibata A: An immunosuppressant compound, FK-506, prevents progression of autoimmune myocarditis in rats. Clin Immunol Immunopathol 1992, 62:321-326.
82. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 72:3366-3370.
83. Rook AH, Masur H, Lane C: Interleukin-2 enhances the depresssed natural killer and cytomegalovirus-specific cytotoxic immune deficiency syndrome. J Clin Invest 1983, 72:398-403.
84. Siegel JP, Rook AH, Djeu JY, Quinnan GV: Interleukin 2 therapy in infectious disease: rationale and prospects. Infection 1985, 13(suppl 2):212-219.
85. Matsumori A, Kawai C: An experimental model for congestive heart failure following encephalomyocarditis virus myocarditis in mice. Circulation 1982, 62:1230-1235.
86. Matsumori A, Crumpacker CS, Abelmann WH: Prevention of viral myocarditis with recombinant human leukocyte interferon-alpha A/D in a murine model. J Am Coll Cardiol 1987, 9:1320-1329.
87. Matsumori A, Tomioka N, Kawai C: Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J 1988, 115:1229-1237.
88. Kishimoto C, Crumpacker CS, Abelmann WH: Prevention of murine coxsackie B3 viral myocarditis and associated lymphold organ atrophy with recombinant human leucocyte interferon alpha A/D. Cardiovasc Res 1988, 22:732-738.
89. Kandolf R, Canu A, Hofschneider PH: Coxsackie 83 virus can replicate in cultured human fetal heart cells and is inhbited by interferon. J Mol Cell Cardiol 1985, 17:167-172.
90. Lutton CW, Gauntt CJ: Ameliorating effect of IFN-β and anti-IFN-β on coxsackievirus B3-induced myocarditis in mice. J Interferon Res 5:137-142.
91. Stille Siegener, M, Heim A, Figulla HR: Subclassification of dialed cardiomyopathy and interferon treatment Eur Heart J 1995, 16(suppl O):147-149. In 77 consecutive biopsies enteroviral RNA was detected by in situ hybridization. Treatment with interferon alfa (3 million units subcutaneously every other day for 6 months) was given in four enterovirus-positive patients. In two of them enteroviral RNA was eliminated. All four improved hemodynamically and clinically. In addition, hemodynamics in the enterovirus-positive patients (treated and untreated) showed better improvement than hemodynamics in the enterovirus-negative patients.
92. Miric M, Miskovic A, Vasiljevic JD, Keserovic N, Pesic M: Interferon and thymic hormones in the therapy of human myocarditis and idiopathic dilated cardiomyopathy. Eur Heart J 1995, 16(suppl O):150-157. First prospective, randomized, open-label 3-month treatment trial with interferon or thymic hormones versus conventional heart failure treatment in 40 patients with biopsy-proven myocarditis or with idiopathic dilated cardiomyopathy. Whereas no effect on survival was noted, hemodynamic improvement was significant in the patients treated with interferon and thymic hormones. The results are remarkable despite the fact that patients were not screened for viral persistence and no differentiation was made with respect to the presence of infiltrates (myocarditis vs idiopathic dilated cardiomyopathy).
93. Costanzo-Nordin MR, Reap EA, O'Connell JB, Robinson JA, Scanlon PJ: A nonsteroid anti-inflammatory drug exacerbates coxsackie B3 murine myocarditis. J Am Coll Cardiol 1985, 6:1078-1086.
94. Rezkalla S, Khatib G, Khatib R: Coxsackievirus B4 murine myocarditis: deleterious effects of nonsteroidal anti-inflammatory agents. J Lab Clin Med 1986, 107:393-399.
95. Gudvangen RJ, Duffey PS, Paque RE, Gauntt CJ: Levamisol exacerbates coxsackievirus B3-induced murine myocarditis. Infect Immun 1983, 41:1157-1162.
96. Estrin M, Smith C, Huber SA: Coxsackievirus B-3 myocarditis: T-cell autoimmunity to heart antigens is resistant to cyclosporin-A treatment Am J Pathol 1986, 125:244-251.
97. McManus BM, Han L, Caruso R, Stratta RJ, Wilson JE: Impact of FK 506 on myocarditis in the enteroviral murine model. Transplant Proc 1991, 23:3365-3367.
98. Chow LH, Beisel KW, McManus BM: Enteroviral infection of mice with severe combined immunodeficiency: evidence for direct viral pathogenesis of myocardial injury. Lab Invest 1992, 66:24-31.
99. Tarleton RL, Sun J, Zhang L, Postan M: Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas' disease. Infect Immun 1994, 62:1820-1829. Demonstration of exacerbation of Chagas myocarditis by immunosuppression-induced depletion of T cells, which led to an increase of the causative agent.
100. Zhang S, Kodama M, Hanawa H, Izumi T, Shibata A, Masani F: Effects of cyclosporine, prednisolone and aspirin on rat autoimmune giant cell myocarditis. J Am Coll Cardiol 1993, 21:1254-1260.
101. Kodama M, Hanawa H, Zhang S, Saeki M, Koyama S, Hosono H, Miyakita Y, Katoh K, Inomata T, Izumi T, Shibata A: FK 506 Therapy of experimental autoimmune myocarditis after onset of the disease. Am Heart J 1993, 126:1385-1392.
102. Hanawa H, Kodama M, Inomata T, Izumi T, Shibata A, Tuchida M, Matsumoto Y, Abo T: Anti-alpha beta T cell receptor antibody prevents the progression of experimental autoimmune myocarditis. Clin Exp Immunol 1994, 96:470-475. Remarkable experimental study demonstrating the T cell dependence of a myosin-induced giant cell myocarditis in rats and the improvement by direct blocking of the T cell receptor.
103. Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T, Suzuki K, Shibata A: Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994, 75:278-284. In myosin-induced giant cell myocarditis in rats, the later stages of the disease resemble dilated cardiomyopathy, underscoring the concept that autoimmune myocarditis can lead to dilated heart muscle disease.
104. Wegmann KW, Zhao W, Griffin AC, Hickey WF: Identification of myocarditogenic peptides derived from cardiac myosin capable of inducing experimental allergic myocarditis in the Lewis rat: the use of a class II binding motif in selecting self-reactive peptides. J Immunol 1994, 153:892-900. Sophisticated experimental study with myocarditogenic peptides from myosin for the generation of myocarditis, with establishment of myosin-specific T-cell lines causing myocarditis by adoptive transfer.
105. Sharaf AR, Narula J, Nicol PD, Southern JF, Khaw BA: Cardiac sarcoplasmic reticulum calcium ATPase: an autoimmune antigen in experimental cardiomyopathy. Circulation 1994, 89:1217-1228. Mononuclear myocarditis can be induced experimentally by immunization with cardiac sarcoplasmic reticulum ATPase. A monoclonal antibody to this enzyme induced myocytolysis but no infiltrate. This may support the concept of serous inflammation (without infiltrate) or stress the fact that inflammatory infiltrates are not obligatory after a humoral immune assault to the heart that damages the myocardium.
106. Penninger JM, Neu N, Timms E, Wallace VA, Koh DR, Kishihara K, Pummerer C, Mark TW: Induction of experimental autoimmune myocarditis in mice lacking CD3 or CD8 molecules. J Exp Med 1993, 178:1837-1842.
107. Schulze K, Becker BF, Schultheiss HP: Autoimmunity to an intracellular protein: antibodies to the ADP/ATP carrier penetrate into myocardial cells and disturb energy metabolism in vivo. Circ Res 1991, 64:179-192.
108. Schwimmbeck PL, Badorff C, Schultheiss HP, Strauer BE: Transfer of human myocarditis Into severe combined immunodeficiency mice. Circ Res 1994, 75:156-164. Severe combined immunodeficiency mice are used as indicator system after transfer of human lymphocytes to demonstrate that T cells sensitized to the myocardial ADP/ATP-carrier can induce myocarditis.
109. 1-adrenoceptor in sera of patients with dilated cardiomyopathy as an agonist antibody. This may be of importance for the advocated β-blocker treatment in patients with dilated cardiomyopathy.
110. Hasenfuss G, Holubarsch C, Hermann HP, Astheimer K, Pieske B, Just H: Influence of the force-frequency relationship on hemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J 1994, 15:164-170.
111. 1 Markel ML, Hoit BD, Walsh RA: Regression of a dilated cardiomyopathy after radiofrequency ablation of incessant supraventricular tachycardia. Am Heart J 1993, 126:1469-1472 77.
112. Sekiguchi M, Yu Z-X, Hasumi M, Hiroe M, Morimoto S, Nishikawa T: Histopathologic and ultrastructural observations of acute and convalescent myocarditis: a serial endomyocardial biopsy study. Heart Vessel 1985, 1(suppl 1):143-153.
113. 1 Holmes DR, Reeder GS: Diagnosis of active lymphocytic myocarditis by endomyocardial biopsy. Quantitative criteria for light microscopy. Mayo Clin Proc 1982, 57:419-425.
114. Fenoglio JJ, Ursell PC, Kellog CF, Drusin RE, Weiss MB: Diagnosis and classification of myocarditis by endomyocardial biopsy. N Engl J Med 1983, 308:12-18.
115. Hess OM: Klinik, Diagnostik und Therapie der Myokarditis. Schweiz Rundschau Med Prax 1984, 73:817.
116. Zea-Cheng CS, Tsai CC, Palmer DC, Codd JE, Rennington DG, Williams GA: High incidence of myocarditis by endomyocardial biopsy in patients with idiopathic congestive cardiomyopathy. J Am Coll Cardiol 1984, 3:63-67.
117. Daly K, Richardson PJ, Olsen EGJ: Acute myocarditis: role of histological and virological examination in the diagnosis of immunosuppressive treatment B Heart J 1984, 51:30-35.
118. Vignola H, Aonuma K, Swaye PS, et al.: Lymphocytic myocarditis presenting as unexplained ventricular arrhythmias: diagnostic with endomyocardial biopsy and response to immunosuppression. J Am Coll Cardiol 1984, 4:811-819.
119. Dec WG, Palacios IG, Fallen JT, Southern JF: Active myocarditis in the spectrum of acute dilated cardiomyopathies. N Engl J Med 1985, 312:885-890.
120. Hosenpud JD, McAnulty JH, Niles NR: Lack of objective improvement in ventricular systolic function in patients with myocarditis treated with azathioprine and prednisone. J Am Coll Cardiol 1985, 6:217-222.
121. Camerini F, Salvi A, Bussani R, et al.: Immunosuppressive treatment in myocarditis. In New Concepts in Viral Heart Disease. Edited by Schultheiß HP. Heidelberg: Springer 1988:402-425.
122. Hobbs RE, Pelegrin D, Ratliff NB, et al.: Lymphocytic myocarditis and dilated cardiomyopathy: treatment with immunosuppressive agents. Cleve Clin J Med 1989, 56:628-635.
123. Chan KY, Iwahara M, Benson LN, Wilson GJ, Freedom RM: Immunosuppressive therapy in the management of acute myocarditis in children; a clinical trial. J Am Coll Cardiol 1991, 17:458-460.
124. Jones RS, Herskowitz A, Hutchins MG, Baughman LK: Effects of immunosuppressive therapy in biopsy proven myocarditis and borderline myocarditis in left ventricular function. Am J Cardiol 1991, 68:370-376.
125. Schultheiß HP, Kühl U, Janda I, Schanwell M, Strauer BE: Immunosuppressive therapy in myocarditis. Herz 1992, 17:112-121.
126. Schultheiß HP: Die dilatative Kardiomyopathie-eine chronische Myokarditis? Neue Aspekte zur Diagnostik und Therapie. Z Kardiol 1993, 82(suppl 4):25-32.